Inventiva reports its 2023 first-half financial results and provides a corporate update
Cash and cash equivalents at €31.2 million, short-term deposits at €0.05 million1, and long-term deposit at €9.3 million2, as of...
Pharmaceutical
Stephen Dilly Receives the 2023 Bloom Burton Award
Toronto, Ontario--(Newsfile Corp. - September 29, 2023) - Bloom Burton & Co. ("Bloom Burton") is pleased to announce Stephen Dilly,...
Poolbeg Pharma PLC Announces Favourable Conclusion of Patent Opposition
Positive Conclusion Reached in Immunomodulator I Patent OppositionPatent opposition hearing cancelledLONDON, UK / ACCESSWIRE / September 29, 2023 / Poolbeg...
Bionxt Solutions Announces Closing of Second Tranche of Non-Brokered Private Placement
VANCOUVER, BC / ACCESSWIRE / September 28, 2023 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:4XT) is pleased to...
Medexus and medac Agree to Amend US Treosulfan Agreement
Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - September 28, 2023) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) is pleased to...
Rancho Biosciences Will Be Exhibiting at the Festival of Genomics & Biodata 2023
SAN DIEGO, CA / ACCESSWIRE / September 28, 2023 / Rancho Biosciences, the leading Data Science Service company, will be...
“The Future Is Bright” With Opportunities to Grow: BioAlberta’s State of the Industry Reports on Alberta’s Life Sciences and Healthcare Industry
EDMONTON, Alberta--(BUSINESS WIRE)--BioAlberta has published its 2023 State of the Industry (SOI) report. This year’s report includes new insights and...
Lexicon to Present Post Hoc Analysis of Scored Clinical Trial at the Heart Failure Society of America (HFSA) Annual Scientific Meeting 2023
INPEFA® (sotagliflozin) recently approved by FDA for treatment of heart failure SCORED was one of two randomized, double-blind, placebo-controlled Phase...
Nusano to Participate in October Investor Conferences
NEW YORK, Sept. 28, 2023 (GLOBE NEWSWIRE) -- Nusano, Inc., a company reshaping the production of cancer-fighting radioisotopes, today announced...
Viralgen Vector Core and Elpida Therapeutics partner to manufacture gene therapy medicines for anticipated Spastic Paraplegia 50 (SPG50) and Charcot-Marie-Tooth disease type 4J (CMT4J) clinical trials
Trial participants with Spastic Paraplegia 50 (SPG50) and Charcot-Marie-Tooth disease type 4J (CMT4J) could benefit from this joint effort to...
Biomea Fusion Announces FDA and Health Canada Clearance of the Expansion Cohorts of the Ongoing COVALENT-111 Phase II Study
The FDA and Health Canada have cleared the initiation of the expansion portion of COVALENT-111, which will evaluate BMF-219 administered...
NurExone Appoints Dr. Reuter Investor Relations in Europe
TORONTO and HAIFA, Israel, Sept. 28, 2023 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (FSE: J90) (NRX.V) (the “Company”...
Soleno Therapeutics Announces Pricing of Approximately $120 Million Underwritten Public Offering of Common Stock and Concurrent Private Placement of Common Stock and/or Pre-Funded Warrants
REDWOOD CITY, Calif., Sept. 28, 2023 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Nasdaq:SLNO), (“Soleno” or the “Company”), a clinical-stage biopharmaceutical...
Cell-Easy is pleased to welcome Mrs. Gisele Deblandre, formerly CSO at MaSTherCell, as Chief Scientific Officer
Gisele Deblandre, Cell-Easy's Chief Scientific Officer We're thrilled to welcome Gisele Deblandre as our new Chief Scientific Officer! TOULOUSE, France,...
Ardelyx Announces Publication of Positive Results from T3MPO-3 Long-Term Open-Label Safety Trial of Tenapanor for IBS-C in the Journal of Neurogastroenterology and Motility
WALTHAM, Mass., Sept. 28, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to...
Merck KGaA, Darmstadt, Germany and Quris-AI Expand Collaboration
Companies Extend Collaboration After Successful Preclinical Study Assessed the Quris-AI BioAI Drug Safety PlatformBOSTON and TEL AVIV, Israel, Sept. 28,...
GigaGen Partners with the National Cancer Institute to Advance Oncology Drug Candidate GIGA-564
Collaboration sets stage for GigaGen’s first oncology asset to enter clinical development GIGA-564 is a differentiated anti-CTLA4 antibody with potential...
Onconova Therapeutics to Present a Late-Breaking Abstract on Rigosertib at the 2023 EADV Congress
NEWTOWN, Pa., Sept. 28, 2023 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova”, the “Company”), a clinical-stage biopharmaceutical company...
Lisata Therapeutics Announces Participation in Upcoming Conferences in October
BASKING RIDGE, N.J., Sept. 28, 2023 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage...
Clene Announces Peer-Reviewed Publication Describing CNM-Au8 Catalytic Neuroprotective Mechanism of Action
Novel catalytic mechanism of CNM-Au8 reveals its promise as a versatile new treatment to address multiple assaults on neuronal health...